Drugs / Delta-tocotrienol
Delta-tocotrienol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01446952 | Sep 2011 → Sep 2012 | malignant pancreatic neoplasm | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06519097 | Jul 2024 → Sep 2026 overdue | pancreatic intraductal papillary-mucinous neoplasm | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Delta-tocotrienol | “treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.” NCT06519097 ↗ |
| Known as | Vitamin E δ-Tocotrienol | “Vitamin E δ-Tocotrienol will be administered orally as a single agent once.” NCT01446952 ↗ |
| Known as | δ-tocotrienol | “treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.” NCT06519097 ↗ |
| Modality | Other / unclassified | “Tocotrienols are natural vitamin E compounds” NCT06519097 ↗ |
| Route | Oral | “Vitamin E δ-Tocotrienol will be administered orally as a single agent once.” NCT01446952 ↗ |